Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pembrolizumab in Glioblastoma Multiforme: NCT06157541 Clinical Landscape Report 2026
15 October 2026
NCT06157541 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sufenidone in Idiopathic Pulmonary Fibrosis: NCT06160440 Clinical Landscape Report 2026
15 October 2026
NCT06160440 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
68Ga-FAPI in Fibrosis, Liver: NCT06160271 Clinical Landscape Report 2026
15 October 2026
NCT06160271 clinical landscape for Fibrosis, Liver: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Retifanlimab in Recurrent Glioblastoma: NCT06160206 Clinical Landscape Report 2026
15 October 2026
NCT06160206 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efruxifermin in Metabolic Dysfunction Associated Steatohepatitis: NCT06161571 Clinical Landscape Report 2026
15 October 2026
NCT06161571 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
DFP-13318 in Ependymoma: NCT06161519 Clinical Landscape Report 2026
15 October 2026
NCT06161519 clinical landscape for Ependymoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HSK-31679 in Metabolic Dysfunction Associated Steatohepatitis: NCT06168383 Clinical Landscape Report 2026
15 October 2026
NCT06168383 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Lerapolturev in Glioblastoma Multiforme: NCT06177964 Clinical Landscape Report 2026
15 October 2026
NCT06177964 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Monepantel in Motor Neuron Disease: NCT06177431 Clinical Landscape Report 2026
15 October 2026
NCT06177431 clinical landscape for Motor Neuron Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Aleeto in Amyotrophic Lateral Sclerosis: NCT06181526 Clinical Landscape Report 2026
15 October 2026
NCT06181526 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AGMB-447 in Idiopathic Pulmonary Fibrosis: NCT06181370 Clinical Landscape Report 2026
15 October 2026
NCT06181370 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT06186440 Clinical Landscape Report 2026
15 October 2026
NCT06186440 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.